Today our subsidiary Axovant announced topline results from its Phase 3 MINDSET trial of intepirdine in mild-to-moderate Alzheimer’s disease. Unfortunately, intepirdine did not achieve a statistically significant result on the primary endpoints of the study.
Patients and physicians have witnessed an unrelenting series of failures in Alzheimer’s disease trials over the past decade and a half. Regrettably this is one more to add to the list, but the contributions of the trial participants were not in vain: researchers will generate valuable information from the trial that we hope will improve future trials in this area.
Alzheimer’s disease is one of the most difficult areas of drug development. We are proud of the tireless efforts of the team at Axovant who conducted the MINDSET trial in the face of those challenges. Today’s results are a setback for our company, and more importantly for patients with Alzheimer’s disease. But it is not the end of the road. Axovant remains committed to future research in this area, and we are rooting for all companies who share that commitment.
At Roivant, we remain committed to taking bold bets in important disease areas that require additional focus and investment. This includes our efforts to develop innovative therapies for conditions like endometriosis and uterine fibroids at Myovant, complete DiGeorge Syndrome and Farber disease at Enzyvant, inflammatory skin conditions at Dermavant, urologic conditions at Urovant, and other disease areas as well. Some of those efforts will succeed. Others will fail. We owe it to patients to take those risks, and we remain undeterred in pursuing our mission.